High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma

International Journal of Cancer

Volumn 79, Issue 6, 1998, Pages 588-595

  Borgfeldt, Christer ^a   Casslén, Bertil ^a   Liu, Chun Li ^a   Hansson, Stefan ^b   Lecander, Ingegerd ^a   Átedt, Birger ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; UROKINASE;

ARTICLE; BENIGN TUMOR; CANCER STAGING; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALIGNANT NEOPLASTIC DISEASE; OVARY CARCINOMA; PRIORITY JOURNAL; RNA ANALYSIS; TISSUE HOMOGENATE; TUMOR DIFFERENTIATION;

CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RNA, MESSENGER; STROMAL CELLS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031769894     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981218)79:6<588::AID-IJC6>3.0.CO;2-W     Document Type: Article

References (24)

1. ANDREASEN, P.A., KJOLLER, L., CHRISTENSEN, L. and DUFFY, M.J., The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72, 1-22 (1997).
2. ÅSTEDT, B. and HOLMBERG, L., Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature (Lond.), 261, 595-597 (1976).
3. ÅSTEDT, B., HOLMBERG, L., LECANDER, I. and THORELL, J., Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures. Europ. J. Cancer, 17, 239-244 (1981).
4. BONTA, I.L. and BEN EFRAIM, S., Involvement of inflammatory mediators in macrophage antitumor activity. J. Leukocyte Biol., 54, 613-626 (1993).
5. CAMIOLO, S.M., SIUTA, M.R. and MADEJA, J.M., Improved medium for extraction of plasminogen activator from tissue. Prep. Biochem., 12, 297-305 (1982).
6. CASSLÉN, B., BOSSMAR, T., LECANDER, I. and ÅSTEDT, B., Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Europ. J. Cancer, 30A, 1-302-1309 (1994).
7. CHAMBERS, S.K., GERTZ, JR., R.E., IVINS, C.M. and KACINSKI, B.M., The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer, 75, 1627-1633 (1995).
8. DUFFY, M.J., Proteases as prognostic markers in cancer. Clin. Cancer Res., 2, 613-618 (1996).
9. DUMLER, I., PETRI, T. and SCHLEUNING, W.D., Interaction of urokinase-type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett., 322, 37-40 (1993).
10. DUMLER, I., PETRI, T. and SCHLEUNING, W.D., Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett., 343, 103-106 (1994).
11. GOLD, L.I., SAXENA, B., MITTAL, K.R., MARMOR, M., GOSWAMI, S., NACTIGAL, L., KORC, M. and DEMOPOULOS, R.I., Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res., 54, 2347-2358 (1994).
12. GRIMALDI, G., DI FIORE, P., LOCATELLI, E.K., FALCO, J. and BLASI, F., Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells. EMBO J., 5, 855-861 (1986).
13. KOBAYASHI, H., MONIWA, N., SUGIMURA, M., SHINOHARA, H., OHI, H. and TERAO, T., Increased cell-surface urokinase in advanced ovarian cancer. Jpn. J. Cancer Res., 84, 633-640 (1993).
14. KUHN, W., PACHE, L., SCHMALFELDT, B., DETTMAR, P., SCHMITT, M., JÄNICKE, F. and GRAEFF, H., Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol., 55, 401-409 (1994).
15. ODEKON, L.E., SATO, Y., and RIFKIN, D.B., Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J. cell. Physiol., 150, 258-263 (1992).
16. PETTERSSON, F., Annual report on the results of treatment in gynecological cancer. In: F. Pettersson, W.T. Creasman, J.H. Shepherd and S. Pecorelli (eds.), Annual report on The results of treatment in gynecological cancer, 22, pp. 1-277, international Federation of Gynecology and Obstetrics, Stockholm (1995).
17. PUJADE LAURAINE, E., LU, H., MTRSHAHI, S., SORIA, J., SORIA, C., BERNADOU, A., KRUITHOF, E.K., LUNEN, H.R. and BURTIN, P., The plasminogen-activation system in ovarian tumors. Int. J. Cancer, 55, 27-31 (1993).
18. PYKE, C., GRAEM, N., RALFKIAER, E., RØNNE, E., HØYER HANSEN, G., BRUNNER, N. and DANØ, K., Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res., 53, 1911-1915 (1993).
19. PYKE, C., KRISTENSEN, P., RALFKIAER, E., GRØNDAHL HANSEN, J., ERIKSEN, J., BLASI, F and DANØ, K., Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Amer. J. Pathol., 138, 1059-1067 (1991).
20. STOPPELLI, M.P., CORTI, A., SOFFIENTINI, A., CASSANI, G., BLASI, F. and ASSOIAN, R.K., Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. nat. Acad. Sci. (Wash.), 82, 4939-4943 (1985).
21. VASSALLI, J.D., BACCINO, D. and BELIN, D., A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol., 100, 86-92 (1985).
22. + RNA. Proc. nat. Acad. Sci. (Wash.), 81, 4727-4731 (1984).
23. WHITFIELD, JR., H.J., BRADY, L.S., SMITH, M.A., MAMALAKI, E., FOX, R.J. and HERKENHAM, M., Optimization of cRNA probe in situ hybridization methodology for localization of glucocorticoid receptor mRNA in rat brain: a detailed protocol. Cell. mol. Neurobiol., 10, 145-157 (1990).
24. WILHELM, O., WEIDLE, U., HOHL, S., RETTENBERGER, P., SCHMITT, M. and GRAEFF, H., Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett., 337, 131-134 (1994).